Evogene Ltd.

Report azionario NasdaqCM:EVGN

Capitalizzazione di mercato: US$7.8m

Evogene Gestione

Criteri Gestione verificati 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Ofer Haviv

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEO21.8yrs
Proprietà del CEOn/a
Durata media del management2.6yrs
Durata media del Consiglio di amministrazione2.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • Oct 12

Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rots

Evogene (NASDAQ:EVGN) said its unit Lavie Bio filed a registration package to the U.S. Environmental Protection Agency (EPA) for LAV.311, a bio-fungicide targeting fruit rots and powdery mildews. LAV.311 is based on a bacteria which is naturally present and has shown control of fruit rots and powdery mildew in grapes, strawberries, cucurbits, and fruiting vegetables, in over 30 trials conducted in the U.S., Europe and Israel, the company said in an Oct. 12 press release. "We are pleased to have reached this key product milestone and we are targeting the 2024 growing season for the commercial launch of this product," said Lavie CEO Guri Oron. EVGN -2.87% to $0.68 premarket Oct. 12
Seeking Alpha • Sep 21

Evogene unit launches 2nd-gen medical cannabis products in Israel

Evogene's (NASDAQ:EVGN) unit Canonic launched its second-generation medical cannabis products in Israel. The first product from this line is expected to debut for patients in early October and the rest will follow in the last quarter of the year to Q1 2023. The second-generation products are characterized by high THC and unique terpene profiles, the company said in a Sept. 21 press release. EVGN +1.33% to $0.94 premarket Sept. 21
Seeking Alpha • Sep 14

Lavie Bio appoints Guri Oron as CEO

Lavie Bio, a subsidiary of Evogene (NASDAQ:EVGN) notifies the appointment of Guri Oron as CEO of Lavie Bio, effective as of September 18, 2022. Most recently, Mr. Oron served at Viridix Ltd., an ag-tech company focused on precision irrigation.
Seeking Alpha • Aug 31

Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33M

Evogene press release (NASDAQ:EVGN): Q2 GAAP EPS of -$0.42 misses by $0.23. Revenue of $0.55M (+292.9% Y/Y) beats by $0.33M.
Seeking Alpha • Aug 25

Evogene regains compliance with Nasdaq's minimum bid price requirement

Evogene (NASDAQ:EVGN) said it has regained compliance with Nasdaq's listing rule, which requires the computational biology company's ordinary shares to maintain a minimum bid price of $1.00 per share. The stock exchange has determined compliance after the closing bid price per share was at $1.00 or greater for prior 10 consecutive business days. Nasdaq now considers the matter closed. Shares were trading +2.63% pre-market. Source: Press Release
Seeking Alpha • Aug 17

Evogen stock rises after unit gets $10M investment from ICL under collaboration agreement

Shares of Evogene (NASDAQ:EVGN), a developer of life-science based products, rose as much as 10.2% to $1.3 in Wednesday late afternoon trading after its unit Lavie Bio entered into a collaboration agreement with specialty minerals company ICL (NYSE:ICL). Under the deal, ICL will invest $10M in Lavie Bio, which develops microbiome-based products for use in the food and agriculture industry. The Israeli companies announced the deal after hours on Tuesday. The collaboration would focus on developing bio-stimulant products to enrich the efficiency of fertilizers, they said. Evogene (EVGN) shares had pared some gains and were trading 6.8% higher as of 1522 ET, while ICL stock was -0.9% at $10.04.
Seeking Alpha • Mar 22

Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus

Evogene acts as a computational biology technology hub; $50M market cap, $54M cash, 5 subsidiaries (4 of which are valuable). The article discusses subsidiaries Biomica, Lavie Bio and AgPlenus. Biomica's lead product BMC128, 4 strain live microbiome consortia in immuno-oncology, is proceeding to clinical trials in Israel in Q2 2022, in combination with Bristol Myers' PD-1 Opdivo. Lavie Bio recently commercially launched result™, a microbiome-based ag-stimulant to increase yield and profitability in spring wheat. Modest initial 2022 sales are expected to increase in 2023 and beyond. AgPlenus is an ag-chemical company. Its lead product APH1 is a novel mode of action herbicide in the near "optimized lead" stage. A deal for APH1could be announced this year. The author believes that Evogene is currently undervalued. With numerous upcoming catalysts in 2022/2023, patient risk-tolerant investors could be handsomely rewarded in the next few years.
Seeking Alpha • Mar 03

Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)

Evogene is a computational biology company that acts a technology hub, creating life science divisions and subsidiaries. Canonic is a subsidiary focused on discovering and developing non-GMO medical cannabis products. In October 2021, Canonic commercially launched G150 and G200, its first two MetaYield medical cannabis products in Israel which appears to be a success. Canonic has Israel's largest Cannabis R&D facility, is fully licensed, owns a state of the art 22,000 square foot greenhouse and molecular labs. It is progressing preclinically (and soon clinically) with its Precise medical cannabis program focused on the treatment of pain and inflammation. Canonic has recently begun shipping its proprietary seedling plants to Portugal in anticipation of a European launch in 2023. A U.S. launch is expected in 2024.
Seeking Alpha • Sep 14

Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market

Canonic introduces their new proprietary cannabis strains and begins limited distribution in Israel. The company will make a full commercial release of the new products in 2022. Evogene’s other subsidiary, Lavie Bio, plans a commercial release of their bio-stimulate in 2022. The company’s Q2-2021 quarterly report shows net loss and low revenues, but plenty of operating cash. I give the company a neutral rating and recommend investors watch their developments and await revenue catalysts.

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Ofer Haviv rispetto agli utili di Evogene?
DataCompenso totaleStipendioUtili della società
Jun 30 2026n/an/a

-US$18m

Mar 31 2026n/an/a

-US$19m

Dec 31 2025n/an/a

-US$14m

Sep 30 2025n/an/a

-US$11m

Jun 30 2025n/an/a

-US$13m

Mar 31 2025n/an/a

-US$15m

Dec 31 2024US$424kUS$374k

-US$13m

Sep 30 2024n/an/a

-US$24m

Jun 30 2024n/an/a

-US$19m

Mar 31 2024n/an/a

-US$21m

Dec 31 2023US$401kUS$390k

-US$20m

Sep 30 2023n/an/a

-US$20m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$25m

Dec 31 2022US$464kUS$415k

-US$27m

Sep 30 2022n/an/a

-US$31m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$530kUS$420k

-US$28m

Sep 30 2021n/an/a

-US$29m

Jun 30 2021n/an/a

-US$26m

Mar 31 2021n/an/a

-US$24m

Dec 31 2020US$592kUS$367k

-US$23m

Sep 30 2020n/an/a

-US$21m

Jun 30 2020n/an/a

-US$21m

Mar 31 2020n/an/a

-US$21m

Dec 31 2019US$538kUS$366k

-US$18m

Compensazione vs Mercato: Dati insufficienti per stabilire se la retribuzione totale di Ofer sia ragionevole rispetto ad aziende di dimensioni simili nel mercato US.

Compensazione vs guadagni: La retribuzione di Ofer è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Ofer Haviv (60 yo)

21.8yrs
Mandato
US$424,000
Compensazione

Mr. Ofer Haviv, CPA, served as Interim Chief Executive Officer of Lavie Bio Ltd. since January 2023. He has been Chief Executive Officer and President of Evogene Limited since December 2004 and served as i...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Ofer Haviv
CEO, President21.8yrsUS$424.00kNessun dato
Yoash Zohar
Chief Executive Officer of Casterra Ag Ltd.2.7yrsUS$583.00kNessun dato
Dan Gelvan
Chief Executive Officer of Ag Plenus Ltd.2.6yrsUS$369.00kNessun dato
Ilia Zhidkov
Chief Technology Officerless than a yearNessun dato0%
$ 0
Liat Wejgman
Vice President of Human Resources4.7yrsNessun datoNessun dato
Gabi Tarcic
Chief Development Officerless than a yearNessun dato0.0071%
$ 559.4
2.6yrs
Durata media
59yo
Età media

Gestione esperta: Il team dirigenziale di EVGN è considerato esperto (durata media dell'incarico 2.6 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Ofer Haviv
CEO, President1.5yrsUS$424.00kNessun dato
Dan Falk
Independent Director4.8yrsNessun dato0%
$ 0
Nir Nimrodi
Independent Chairman4yrsNessun dato0%
$ 0
Leon Recanati
Independent Director21.3yrsNessun dato8.5%
$ 666.3k
Yael Margolin
Directorno dataNessun datoNessun dato
Yoshinori Oikawa
Directorno dataNessun datoNessun dato
Sarit Weiss-Firon
Independent Director10.1yrsNessun dato0%
$ 0
John Irwin
Member of Scientific Advisory Boardless than a yearNessun datoNessun dato
Adrian Percy
Independent Director7.6yrsNessun dato0%
$ 0
Dan Major
Member of Scientific Advisory Boardless than a yearNessun datoNessun dato
2.8yrs
Durata media
61yo
Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di EVGN non è considerato esperto (durata media del mandato 2.8 anni), il che suggerisce un nuovo consiglio.

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/09/13 02:32
Prezzo dell'azione a fine giornata2026/09/11 00:00
Utili2026/06/30
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Evogene Ltd. è coperta da 4 analisti. 1 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Scott HenryAlliance Global Partners
David BegleiterDeutsche Bank
Hoonshik YangOppenheimer & Co. Inc.